BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TRB Chemedica Release: Paris Court Will Rule on the Distribution Rights for Gilead Sciences, Inc. (GILD) Products in Switzerland


10/23/2007 10:10:49 AM

GENEVA, Switzerland, October 23 /PRNewswire/ -- TRB CHEMEDICA INTERNATIONAL S.A. has issued legal proceedings against GILEAD SCIENCE LIMITED in a dispute over the distribution rights of their products Viread(TM), Hepsera(TM), Truvada(TM) and Emtriva(TM) for Switzerland.

TRB CHEMEDICA INTERNATIONAL, a small, family-owned Swiss pharmaceutical company based in Geneva, was granted exclusive rights by GILEAD in 2003 to hold the regulatory approvals with related reimbursements and to distribute their products in Switzerland.

Through substantial investment in scientific support and promotion and an efficient distribution structure, TRB CHEMEDICA INTERNATIONAL achieved sales of SFr. 25 million in 2006.

In addition, TRB CHEMEDICA INTERNATIONAL became the top performer among all of GILEAD's European distributors.

In 2006, GILEAD incorporated a subsidiary in Switzerland, and announced their intention to early terminate the distribution agreements with TRB CHEMEDICA INTERNATIONAL which were contracted to end on 31 December 2010. TRB CHEMEDICA INTERNATIONAL disputed this position, expressing the view that such an early termination would be unlawful.

However, GILEAD terminated the distribution agreements in June 2007 for the end of 2007.

As a consequence, TRB CHEMEDICA INTERNATIONAL will lose a substantial part of its turnover and be obliged to lay off staff, something that has never happened during the 25 years of the company's existence.

TRB CHEMEDICA INTERNATIONAL has now applied to the competent court in Paris, France to rule on the unlawful early termination of the agreements by GILEAD and to compensate TRB CHEMEDICA INTERNATIONAL for the damage caused estimated at SFr. 12 million.

giuseppe.novelli@trbchemedica.com

CONTACT: G. G. Novelli, Director International Corporate Affairs, TRB
Chemedica International S.A., TRB Chemedica International S.A., 12 rue
Michel-Servet, CH - 1211 Geneva 12., Switzerland
giuseppe.novelli@trbchemedica.com, Tel. +41-22-703-49-00,
Tel.+41-22-703-49-20 (Dir.), Fax +41-22-703-49-01



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES